Home > List All Publishers > CHI Insight Pharma Reports

CHI Insight Pharma Reports

CHA Advances Reports are a service of Cambridge Healthtech Advisors. Advances Reports are written by experts who collaborate with CHA to provide a series of reports that evaluate the salient trends in pharmaceutical technology, business, and therapy markets.

Advances Reports offer:

Current information and analysis of R&D technologies, therapeutic markets, and critical business issues.

Analysis of the probability of success for various applications of each technology.

Interviews with key personnel in companies at the forefront of technological advances.

Competitive insight on the business strategies and activities of key companies.

List of reports from CHI Insight Pharma Reports

Toxicogenomics and Predictive Toxicology: Market and Business Outlook 12/1/2004 \| published by: CHI Insight Pharma Reports ... over the past five years that are raising optimism for dramatic improvements in the field. A detailed and insightful business outlook on the strategic, regulatory, and marketplace issues driving growth of toxicogenomic and predictive toxicology ... \| more...	$2,750.00
Microarrays: Technologies, Applications, Markets 11/1/2004 \| published by: CHI Insight Pharma Reports ... covered in detail to present a complete competitive view of the microarray market: • Current and emerging applications of DNA microarray technologies are reviewed and assessed. • Growth trends are analyzed for genome-wide arrays for ... \| more... Search inside this report	$4,200.00
Molecular Imaging Comes of Age: Applications and Impacts in Discovery, Clinical Trials, and Medical Practice 10/1/2004 \| published by: CHI Insight Pharma Reports ... delivery of care. The report presents a comprehensive assessment of the latest trends and developments in molecular imaging, enhanced by the insights of opinion leaders from industry and academia. A market outlook completes the analysis. ... \| more... Search inside this report	$4,200.00
New Directions in Monoclonal Antibodies: Technologies, Markets, Competition 10/1/2004 \| published by: CHI Insight Pharma Reports ... and therapeutic applications. This report examines the more than 110 mAb products currently in clinical trials, as well as the products that are already available and those still at the preclinical stage that are likely ... \| more... Search inside this report	$4,200.00
Successful Outsourcing of Pharmaceutical R&D: Trends and Strategies 9/1/2004 \| published by: CHI Insight Pharma Reports ... together primary interviews with R&D outsourcing managers, extensive public data sources, and a proprietary survey of the outsourcing practices of 72 pharmaceutical and biotech companies, this report: Describes the outsourcing market, identifying salient trends and ... \| more... Search inside this report	$5,400.00
Model Animal Systems: Emerging Applications and Commercial Opportunities in Drug Discovery and Development 6/1/2004 \| published by: CHI Insight Pharma Reports ... this field, the areas of greatest unmet need, and the most important emerging applications. Models discussed include yeast, the nematode (Caenorhabditis elegans), the fruitfly (Drosophila melanogaster), the zebrafish (Danio rerio), the mouse, and the rat. ... \| more... Search inside this report	$4,200.00
Clinical Genomics: The Impact of Genomic Technology on Clinical Trials and Medical Practice 5/1/2004 \| published by: CHI Insight Pharma Reports ... which genomics could directly contribute to clinical practice, evaluates the scientific, technological, legal, and regulatory issues that will have a significant impact on the future adoption of genomics in clinical settings, and discusses the emerging ... \| more...	$2,500.00
High-Content Analysis Market Outlook 3/1/2004 \| published by: CHI Insight Pharma Reports ... for high-content a nalysis (HCA) systems, software, and reagents. Key areas of implementation and growth potential, as well as areas of future development that will also impact the overall market size, are identified and analyzed. \| more...	$2,500.00
2015: Strategic Considerations for the U.S. Pharmaceutical Industry 2/1/2004 \| published by: CHI Insight Pharma Reports ... insightful and creative business strategies to navigate through the challenges, capitalize on the opportunities, and adapt to change. This report offers a thorough analysis of current trends and issues that are challenging high-level decision making, ... \| more... Search inside this report	$3,750.00
Proteins: Selection, Synthesis, and Purification Strategies for Optimizing Drug Discovery 1/1/2004 \| published by: CHI Insight Pharma Reports ... the key to understanding of basic biological processes including disease pathology, diagnosis, and treatment. Proteomics will undoubtedly have a profound impact on the drug discovery and development process. The pervasiveness of protein function and their ... \| more... Search inside this report	$2,150.00
Successful Pharmacogenomics Business Models 11/1/2003 \| published by: CHI Insight Pharma Reports ... future large pharmaceutical drug development model; 2) determine requirements for success for each viable pharmacogenomics strategy; and 3) understand the implications for the pharmaceutical and diagnostics industries. Please Note: The cost of PDF Email Delivery ... \| more...	$3,000.00
Molecular Diagnostics: Technological Advances Fueling Market Expansion 10/1/2003 \| published by: CHI Insight Pharma Reports ... field. The report examines the clinical applications for molecular diagnostics, reviews the breadth of technologies now used or in development, evaluates the major players in this market, and discusses the business and health care implications ... \| more... Search inside this report	$2,150.00
Post-Genomic Target Validation: Next Generation Approaches and Tools for Optimizing Target Selection 9/1/2003 \| published by: CHI Insight Pharma Reports ... race to develop innovative target validation technologies that will yield the most promising drug leads. Based on expert commentary and extensive secondary research, Post-Genomic Target Validation profiles the efforts of the leading competitors in this ... \| more... Search inside this report	$2,150.00
Cancer Genomics: Revolutionizing Treatment and Reshaping Markets through Targeted Therapies 8/1/2003 \| published by: CHI Insight Pharma Reports ... strongly by genomics and related technologies than any other indication area. Cancer arises from genetic changes in cells and hence, the availability of tools to better understand exactly how this occurs is revolutionizing the field. ... \| more... Search inside this report	$2,150.00
Kinases: From Targets to Therapeutics 7/1/2003 \| published by: CHI Insight Pharma Reports ... a variety of indications, including diabetes, inflammatory disorders, and especially cancer. The examples of Gleevec (Novartis) and Herceptin (Genentech) demonstrate that despite small markets, kinase inhibitors for cancer that are effective and cause minimal adverse ... \| more... Search inside this report	$2,150.00
GPCRs: Mining the Richest Vein in Drug Discovery 6/1/2003 \| published by: CHI Insight Pharma Reports ... solutions to the lack of structural information about GPCRs. Pharmaceutical and biotechnology companies have long recognized the therapeutic potential of targeting G protein-coupled receptors (GPCRs). The success of GPCR-targeted drugs is well documented; blockbusters Zyprexa ... \| more... Search inside this report	$2,150.00
Life Science Informatics: From Data to Drugs 4/1/2003 \| published by: CHI Insight Pharma Reports ... particular, has gone through a dramatic boom/bust. At the same time, a large number of IT companies are looking to the drug discovery and development arena as a new market opportunity. Pharmaceutical companies, meanwhile, are ... \| more... Search inside this report	$1,500.00
Advances in Lead Optimization Accelerating Drug Discovery and Development 2/1/2003 \| published by: CHI Insight Pharma Reports ... cost of drug discovery and development, a major shift is occurring in how pharmaceutical companies evaluate drug leads. Whereas researchers used to begin by looking at affinity and potency, a genomics/informatics-based research culture is growing ... \| more... Search inside this report	$1,500.00
Prospects for the Commercialization of Human Monoclonal Antibodies 12/1/2002 \| published by: CHI Insight Pharma Reports ... with a wealth of targets and a desire to reap the benefits of developing their own drugs are partnering with major antibody developers, as well as smaller companies that can convert those targets into potential ... \| more... Search inside this report	$1,500.00
Targeting RNA in Drug Development: Emerging Tools and Therapeutics 12/1/2002 \| published by: CHI Insight Pharma Reports ... pharmaceutical industry. RNA's ability to down- or up-regulate gene expression, interfere with protein function, and provoke immune responses has stirred interest and accelerated an ever-increasing number of products into the pipeline. Numerous challenges remain, including ... \| more... Search inside this report	$1,500.00
High-Content Screening: Parallel Analysis Fuels Accelerated Discovery and Development 8/1/2002 \| published by: CHI Insight Pharma Reports ... to the traditional drug discovery process. Given the high cost of failure in drug development, it is crucial that researchers have tools that provide high-quality information about drug targets. High-Content Screening: Parallel Analysis Fuels Accelerated ... \| more... Search inside this report	$1,500.00
Outlook for DNA Microarrays: Emerging Applications and Insights on Optimizing Microarray Studies 7/1/2002 \| published by: CHI Insight Pharma Reports ... pure research applications toward the clinic. New tools and approaches for microarray analysis. The DNA microarray marketplace is changing rapidly. Microarrays are already widely adopted, and many use2rs are now going beyond exploratory studies. With ... \| more... Search inside this report	$1,500.00
Toxicogenomics and Related Approaches: The Promise of Safer, Smarter Drug Development 5/15/2002 \| published by: CHI Insight Pharma Reports ... expression patterns in target cells or tissues, is emerging as a key approach in screening new drug candidates because it may reveal genetic signatures that can be used to predict toxicity in these compounds. This ... \| more... Search inside this report	$1,500.00
Biochemical Pathway and Systems Analysis for Target Identification and Validation 4/1/2002 \| published by: CHI Insight Pharma Reports ... numerous drug discovery researchers and is central to the strategy of many biopharmaceutical and genomic companies. Biochemical Pathway and Systems Analysis for Target Identification and Validation examines various types of biochemical pathways, including metabolic and ... \| more... Search inside this report	$1,500.00

< prev 1 2 3 4 5 6 next >